These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

878 related articles for article (PubMed ID: 24360911)

  • 21. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism.
    Comerota AJ; Ramacciotti E
    Am J Med Sci; 2016 Jul; 352(1):92-106. PubMed ID: 27432042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials.
    Rojas-Hernandez CM; Oo TH
    Drugs; 2019 Apr; 79(6):621-631. PubMed ID: 30905033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism.
    Barsam SJ; Patel R; Arya R
    Br J Haematol; 2013 Jun; 161(6):764-77. PubMed ID: 23560605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions.
    Riess H; Prandoni P; Harder S; Kreher S; Bauersachs R
    Crit Rev Oncol Hematol; 2018 Dec; 132():169-179. PubMed ID: 30447923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
    Ross JA; Miller MM; Rojas Hernandez CM
    Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis.
    Akin M; Schäfer A; Akin I; Widder J; Brehm M
    Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):92-6. PubMed ID: 26666324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism.
    Bertoletti L; Ollier E; Duvillard C; Delavenne X; Beyens MN; De Magalhaes E; Bellet F; Basset T; Mismetti P; Laporte S
    Pharmacol Res; 2017 Apr; 118():33-42. PubMed ID: 27350265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Venous thromboembolism in patients with cancer: an overview for pharmacists using a case-based approach.
    Pangilinan JM
    J Pharm Pract; 2010 Aug; 23(4):294-302. PubMed ID: 21507829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients: a review of current guidelines.
    Petersen LJ
    Cancer Treat Rev; 2009 Dec; 35(8):754-64. PubMed ID: 19762155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of venous thromboembolism in cancer patients.
    Lee AY
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):93-101. PubMed ID: 19285276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
    Borris LC
    Arch Orthop Trauma Surg; 2010 May; 130(5):583-9. PubMed ID: 19565250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
    Rahme E; Feugère G; Sirois C; Weicker S; Ramos E
    Thromb Res; 2013 Mar; 131(3):210-7. PubMed ID: 23290095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond.
    O'Connell CL; Liebman HA
    Expert Rev Hematol; 2008 Dec; 1(2):175-82. PubMed ID: 21082922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer.
    Walenga JM; Lyman GH
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):1-18. PubMed ID: 23849978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New antithrombotic drugs: potential for use in oncology.
    Levine MN
    J Clin Oncol; 2009 Oct; 27(29):4912-8. PubMed ID: 19738103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding the new emerging oral anticoagulants for venous thromboembolism prophylaxis.
    Welle MK
    Orthop Nurs; 2012; 31(5):265-78; quiz 279-80. PubMed ID: 22968380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New anticoagulants in the management of venous thromboembolism in women.
    Piovella F; Irina Iosub D
    Thromb Res; 2015 Feb; 135 Suppl 1():S5-7. PubMed ID: 25903537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.